首页> 外国专利> Synergistic effect between sphingosine-1-phosphate receptor antagonist and anti-microtubule agent

Synergistic effect between sphingosine-1-phosphate receptor antagonist and anti-microtubule agent

机译：1-磷酸鞘氨醇受体拮抗剂与抗微管剂的协同作用

页面导航

摘要
著录项
相似文献

摘要

This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.

机译：本发明基于以下发现：鞘氨醇-1-磷酸受体拮抗剂（S1P）和至少一种选自抗微管剂的化学治疗剂的施用为癌症提供了意想不到的优越治疗。诸如紫杉烷化合物之类的抗微生物剂是本领域已知的，例如紫杉醇（可从新泽西州普林斯顿的布里斯托尔-迈尔斯·斯奎布（Bristol-Myers Squibb，新泽西州）获得），多西他赛（可从赛诺菲-阿万提斯市Bridgewater，新泽西州获得）。类似的化合物和其他充当抗微管剂的化合物，例如长春新碱（Vincristine，长春新碱（Vincristine），长春新碱（Vinsarar），长春新碱（Vinsarin），长春新碱（Velsarn，VELSAR®）和长春瑞滨（Vinorelbine）），以及类似的化合物。本发明还提供了通过施用治疗有效量的至少一种鞘氨醇-1-磷酸1（S1P1R）受体拮抗剂和至少一种抗微管剂来调节所选细胞群（例如癌细胞）生长的方法。

著录项

公开/公告号JP2012505923A

专利类型
公开/公告日2012-03-08

原文格式PDF
申请/专利权人エグゼリクシス;インコーポレイテッド;
展开▼

申请/专利号JP20110532299
发明设计人シャンカー;ギーサ;ベンツィエン;フラウケ;ラム;ピーター;マシューズ;デイビッド;
展开▼

申请日2009-10-16
分类号A61K45;A61K31/4192;A61K31/475;A61P35;A61P31/18;A61P21;A61P15;A61P13/10;A61P1/04;A61P1/18;A61P13/08;A61P25;A61P35/02;A61P17;A61P1/16;A61P11/02;A61P19;A61P11;A61K31/337;
国家 JP
入库时间 2022-08-21 17:38:32

相似文献

专利
外文文献
中文文献